Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Adamts5 binding immunoglobulin fusion proteins: MerckRecent Research Landscape

Uncontrolled enzymatic degradation of the extracellular matrix leads to irreversible joint tissue loss. These engineered constructs simultaneously inhibit ADAMTS5 and MMP13 to arrest cartilage catabolism.

What technical problems is Merck addressing in Adamts5 binding immunoglobulin fusion proteins?

Cartilage matrix enzymatic degradation

(5)evidences

Irreversible breakdown of aggrecan and collagen by specific proteinases leads to joint failure. Inhibiting these enzymes prevents structural loss in degenerative joint diseases.

Progressive articular cartilage degradation

(1)evidences

Suboptimal delivery routes and dosing regimens limit the therapeutic concentration of ADAMTS5 inhibitors at target sites. Improving administration protocols overcomes physiological barriers to effective protein uptake.